These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22230298)

  • 1. Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine.
    Buchi F; Spinelli E; Masala E; Gozzini A; Sanna A; Bosi A; Ferrari G; Santini V
    Leuk Res; 2012 May; 36(5):607-18. PubMed ID: 22230298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines.
    Berg T; Guo Y; Abdelkarim M; Fliegauf M; Lübbert M
    Leuk Res; 2007 Apr; 31(4):497-506. PubMed ID: 17056112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias.
    Serrano E; Carnicer MJ; Lasa A; Orantes V; Pena J; Brunet S; Aventín A; Sierra J; Nomdedéu JF
    Leuk Res; 2008 Jun; 32(6):944-53. PubMed ID: 18206229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts.
    Gozzini A; Santini V
    Ann Hematol; 2005 Dec; 84 Suppl 1():54-60. PubMed ID: 16228241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Redistribution of H3K27me3 and acetylated histone H4 upon exposure to azacitidine and decitabine results in de-repression of the AML1/ETO target gene IL3.
    Buchi F; Masala E; Rossi A; Valencia A; Spinelli E; Sanna A; Gozzini A; Santini V
    Epigenetics; 2014 Mar; 9(3):387-95. PubMed ID: 24300456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells.
    Flotho C; Claus R; Batz C; Schneider M; Sandrock I; Ihde S; Plass C; Niemeyer CM; Lübbert M
    Leukemia; 2009 Jun; 23(6):1019-28. PubMed ID: 19194470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
    Lowder JN; Taverna P; Issa JP
    Epigenomics; 2015 Oct; 7(7):1083-8. PubMed ID: 26541345
    [No Abstract]   [Full Text] [Related]  

  • 8. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
    Estey EH
    Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
    Song LX; Xu L; Li X; Chang CK; Zhang Y; Wu LY; He Q; Zhang QX; Li X
    Ann Hematol; 2012 Dec; 91(12):1879-86. PubMed ID: 22895556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies.
    Lyons J; Bayar E; Fine G; McCullar M; Rolens R; Rubinfeld J; Rosenfeld C
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1442-50. PubMed ID: 14763130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of decitabine for the treatment of acute myeloid leukemia.
    Ganetsky A
    Ann Pharmacother; 2012 Nov; 46(11):1511-7. PubMed ID: 23115225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A selective activity of DNMTi decitabine on AML1ETO positive cells?
    Santini V
    Leuk Res; 2007 Jun; 31(6):741-2. PubMed ID: 17240447
    [No Abstract]   [Full Text] [Related]  

  • 13. Decitabine has promising clinical activity in chronic myeloid leukemia.
    Expert Rev Anticancer Ther; 2002 Dec; 2(6):620-1. PubMed ID: 12503205
    [No Abstract]   [Full Text] [Related]  

  • 14. Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: achievements and challenges.
    Lübbert M; Kuendgen A
    Cancer; 2015 Feb; 121(4):498-501. PubMed ID: 25336205
    [No Abstract]   [Full Text] [Related]  

  • 15. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells.
    Klisovic MI; Maghraby EA; Parthun MR; Guimond M; Sklenar AR; Whitman SP; Chan KK; Murphy T; Anon J; Archer KJ; Rush LJ; Plass C; Grever MR; Byrd JC; Marcucci G
    Leukemia; 2003 Feb; 17(2):350-8. PubMed ID: 12592335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-sites cleavage of leukemogenic AML1-ETO fusion protein by caspase-3 and its contribution to increased apoptotic sensitivity.
    Lu Y; Peng ZG; Yuan TT; Yin QQ; Xia L; Chen GQ
    Leukemia; 2008 Feb; 22(2):378-86. PubMed ID: 17989718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of AML1-ETO fusion transcript as a prognostic indicator in acute myeloid leukemia.
    Yoo SJ; Chi HS; Jang S; Seo EJ; Seo JJ; Lee JH; Park HS; Park CJ
    Haematologica; 2005 Nov; 90(11):1493-501. PubMed ID: 16266896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia.
    Linggi B; Müller-Tidow C; van de Locht L; Hu M; Nip J; Serve H; Berdel WE; van der Reijden B; Quelle DE; Rowley JD; Cleveland J; Jansen JH; Pandolfi PP; Hiebert SW
    Nat Med; 2002 Jul; 8(7):743-50. PubMed ID: 12091906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner.
    Elsässer A; Franzen M; Kohlmann A; Weisser M; Schnittger S; Schoch C; Reddy VA; Burel S; Zhang DE; Ueffing M; Tenen DG; Hiddemann W; Behre G
    Oncogene; 2003 Aug; 22(36):5646-57. PubMed ID: 12944913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of DNA methylation: beyond myelodysplastic syndromes.
    Fenaux P
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S36-44. PubMed ID: 16341239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.